WaferGen Bio-systems Announces Highly Successful Initial Customer Testing of Its Previously Unannounced Novel Target Enrichment

 WaferGen Bio-systems Announces Highly Successful Initial Customer Testing of
  Its Previously Unannounced Novel Target Enrichment Technology for Next-Gen
                               Sequencing (NGS)

Superior and Uniform Coverage Should Help Facilitate Clinical Applications of
NGS

PR Newswire

FREMONT, Calif., Jan. 8, 2013

FREMONT, Calif., Jan. 8, 2013 /PRNewswire/ --WaferGen Bio-systems, Inc.
(OTCBB: WGBS) today announced the successful completion of a proof-of-concept
study using its newly-developed proprietary nano-qPCR technology for sample
preparation prior to targeted re-sequencing on Next-Gen platforms. The
results can be viewed in white paper form at:

http://www.wafergen.com/wp-content/uploads/2013/01/TargetEnrchmnt_NGS_WPf.pdf

Target enrichment with uniform coverage approaching 100% is difficult to
achieve with current methods and represents a potentially very large unmet
need in the fast-developing market for clinical sequencing. Future
implementations of routine sequencing in diagnostic testing will require
clinical labs to get as close to this goal as possible. WaferGen's
proprietary approach to solving this challenge is based on massively parallel
PCR reactions, where amplification is cleaner and better controlled, thereby
providing superior coverage and uniformity.

"One of the main challenges in conducting accurate and efficient targeted
re-sequencing using next-gen methods is the target enrichment step. The key
goal of complete and uniform coverage is often elusive when relying on the
most frequently used methods of highly multiplexed PCR and/or target capture.
In our study, we have successfully tested a new type of WaferGen's
high-density chip and related system components, on which one is able to
enrich hundreds to thousands of target regions by amplifying each target in an
individual PCR reaction, thereby avoiding multiplexing interference. In a
typical run, excellent sensitivity was reached (covering 96.7% and 97.3% of
the targets >40 fold and >10 fold, respectively), while uniform coverage was
obtained (>93.4% of the targets fell within a 10 fold difference in
coverage). We plan to expand the evaluation and development of this
application on WaferGen's platform," stated Dr. Jo Vandesompele, Professor of
Functional Genomics and Applied Bioinformatics at Ghent University and the
lead author of the study.

Based on the encouraging initial results from Ghent University, as well as
similarly promising results from a second alpha unit at a major US medical
research institution, the Company plans to deploy significant available
resources behind the rapid refinement and commercialization of this
potentially frame-breaking technology. It is contemplated that existing system
components will be complemented by a low-cost cycler and a simple sample
dispenser that will allow the technology to be cost-effectively deployed even
at smaller labs. This technology will add important utility to the SmartChip
System, which already offers a wide array of nano-qPCR applications with
best-in-class flexibility, high levels of sensitivity and dynamic range
without the need for pre-amplification, and a very low cost per reaction.

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Bio-systems, Inc. is an innovative life science company that offers
the SmartChip Real-Time PCR System—a next-generation genetic analysis platform
for profiling and validating molecular biomarkers. It provides a range of
high-throughput capabilities including microRNA and mRNA gene expression
profiling as well as single nucleotide polymorphism (SNP) genotyping. 

For additional information, please see http://www.wafergen.com

Forward Looking Statements

This press release contains certain "forward-looking statements." Such
statements include statements relating to the expected benefits to the Company
of using nano-qPCR technology for target enrichment sample preparation prior
to targeted re-sequencing on next-gen platforms, and other statements relating
to future events that are not historical facts, including statements which may
be preceded by the words "will," "believes" or similar words. Forward-looking
statements are not guarantees of future performance, are based on certain
assumptions and are subject to various known and unknown risks and
uncertainties, many of which are beyond the control of the Company. Actual
results may differ materially from the expectations contained in the
forward-looking statements. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements
is set forth in the Company's filings with the Securities and Exchange
Commission, including the Company's Annual Report on Form 10-K for the year
ended December 31, 2011. Security holders are urged to read these documents
free of charge on the SEC's web site at www.sec.gov. The Company does not
undertake to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.

WaferGen Contact:

John Harland
john.harland@wafergen.com
510-780-2395

SOURCE WaferGen Bio-systems, Inc.

Website: http://www.wafergen.com
 
Press spacebar to pause and continue. Press esc to stop.